Sonexa contains Dexamethasone which is a synthetically prepared glucocorticosteroid. Its main clinical applications are as a steroidal anti-inflammatory agent.
Sonexa contains Dexamethasone which is a synthetically prepared glucocorticosteroid. Its main clinical applications are as a steroidal anti-inflammatory agent. It acts on the Hypothalamic-pituitary-adrenal (HPA) at specific receptors on the plasma membrane. In other tissues, it diffuses across cell membranes and complexes with specific cytoplasmic receptors, which enter the cell nucleus and stimulate protein synthesis. It has anti-allergic anti-toxic, anti-shock, antipyretic and immunosuppressive properties
Sonexa 6 Tablet: Each film-coated tablet contains Dexamethasone USP 6 mg.
1. Rheumatoid arthritis
2. Collagen diseases
3. Inflammatory & allergic disorders
4. Anaphylactic shock
5. Cerebral oedema
6. Nausea & vomiting with chemotherapy
7. Acute adrenocortical insufficiency
8. Urticaria
9. Eczema
10. Skin diseases
11. Hyperplasia & hyperpyrexia
12. Gout
Sonexa 6 Tablet: The initial dosage of Dexamethasone varies from 0.75 to 9 mg per day. In general, corticosteroid dosage depends on the severity of the condition and the response of the patient.
Ocular herpes simplex is an example of absolute contraindication to corticosteroid therapy relative contraindications are: Gastro-intestinal ulcer, acute or chronic infections, osteoporosis, pregnancy, diabetes mellitus, renal insufficiency, hypertension, history of psychotic illness, immediate before prophylactic immunization and finally hypersensitivity to Dexamethasone.
Dexamethasone should be used with caution in the presence of congestive heart failure or hypertension, in patients with diabetes mellitus, epilepsy, glaucoma, infectious disease, chronic renal failure and uremia and in elderly persons.
Hypersensitivity including anaphylaxis and allergic skin reactions have been reported. The incidence of predictable undesirable effects of glucocorticoids correlates with the dosage timing of administration and duration of treatment. Patients on prolonged Dexamethasone therapy are at risk of collapse and possibly death if their daily dose is not increased at times of severe physical stress e.g. injury, surgery or infections The somatic manifestations include growth retardation in children, osteoporosis and aseptic disturbances, and myopathy. Other cushing-like features, characteristic of glucocorticoid excess include truncal obesity, moon-face, oedema, delayed wound healing, glaucoma, and various psychiatric syndromes. These are all generally reversible with discontinuation of Dexamethasone treatment.
Dexamethasone exhibits interaction with phenytoin and phenobarbitone, ephedrine, rifampicin, magnesium trisilicate, salicylate, potassium-depleting diuretics (such as thiazide or frusemide), cardiac glycosides, NSAIDs, anticoagulants, antidiabetics, antihypertensives, barbiturates, carbamazepine, primidone, antimuscarinic agents.
Use in pregnancy: Safety for use during pregnancy has not been established. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hyperthyroidism.
Use in lactation: Corticosteroid appears in breast milk and may suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects, so the patient should stop nursing if the drug is prescribed.
Sonexa 6 Tablet: Each box contains 30 tablets in Alu-PVC blister pack.
FR
DE
